Michael Ciesielski

Company: MimiVax

Job title: CEO

Seminars:

Positive Clinical Updates on Vaccine-Based Approaches; Uncovering their Potential in Combination Therapy 8:45 am

SurVaxM – a first-of-its-kind, patented peptide mimic immunotherapeutic vaccine targeting surviving Phase IIa study of surVaxM plus adjuvant temozolomide for newly diagnosed glioblastomaRead more

day: Conference Day 1